Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT


ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

In a study published in Pharmacogenomics and Personalized Medicine, researchers investigated the impacts of genotype and voriconazole co-administration on tacrolimus (TAC) trough concentration (C0) in pediatric β-thalassemia major (β-TM) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The authors' findings stress the importance of tailoring drug administration based on patients' genotype profiles, as well as tracking patients' TAC concentrations when administering voriconazole.

For patients receiving allo-HSCT, there is a risk of developing graft versus host disease (GVHD) following transplantation. β-TM patients are therefore at risk of GVHD, as allo-HSCT is currently the sole procedure for curing β-TM. TAC has been utilized as a prophylactic following allo-HSCT, but the effects of its concentration alongside patients' genotypes and co-administration of voriconazole has not been well studied.

Patients were administered TAC two days before allo-HSCT, with venous blood samples collected to determine concentrations before and after transplantation. The results concluded that variations in enzymes such as CYP3A4 greatly impacted TAC concentrations when administered orally. Moreover, the co-administration of voriconazole was found to increase TAC concentrations, necessitating lower TAC doses. Lastly, TAC C0 was found to not be highly correlated with efficacy in these patients, suggesting that C0 is not suitable as an indicator of the efficacy of TAC.


Li C, Lu J, Zhou S, et al. Influential factors and efficacy analysis of tacrolimus concentration after allogeneic hematopoietic stem cell transplantation in children with β-thalassemia major. Pharmgenomics Pers Med. 2021;14:1221-1237. Published 2021 Sep 24. doi:10.2147/PGPM.S325103

Related Videos
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Recommendations penned by the American Society of Clinical Oncology and Society for Gynecologic Oncology may be critical in managing the ongoing chemotherapy shortage, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Related Content